Prestige Consumer Healthcare Investigation - May 16

The Story

Levi & Korsinsky has commenced an investigation into Prestige Consumer Healthcare, Inc., saying executives projected $245 million in free cash flow and a 57% adjusted gross margin but weeks later Q4 results fell materially short, and the company had not disclosed a $150 million acquisition, the firm said on May 15. The probe targets officers and directors of $PBH as investors seek clarity on the missed targets and lack of disclosure.

Why It Matters For Your Portfolio

• $245 million projected free cash flow versus materially short Q4 results, a potential signal that cash generation is weaker than disclosed, which could pressure valuation for $PBH.
• 57% projected adjusted gross margin, now in doubt after the shortfall, a development that could squeeze future margin assumptions used in models.
• An undisclosed $150 million acquisition raises governance and disclosure risk, which can increase legal and regulatory scrutiny and heighten short-term volatility.
• Additional flagged data points include 28.05%, 15.18%, and 0.17%, metrics investors may use in scenario analysis as they reassess growth and margin sensitivity.

The Trade

Event-driven and risk-sensitive investors should pay attention, and traders who focus on governance news may find volatility opportunities. Watch for company disclosures, SEC filings, and updates from Levi & Korsinsky for material developments and any clarifying commentary from $PBH.